CD Biosynsis offers premium Sf9 Cells Protein Expression and Purification Services, utilizing the versatile Baculovirus Expression Vector System (BEVS) for the high-yield, large-scale production of complex recombinant proteins. Sf9 cells (derived from Spodoptera frugiperda) are an established eukaryotic system, highly valued for producing proteins that require correct folding, disulfide bond formation, and PTMs (Post-Translational Modifications) that bacterial hosts cannot provide. Our comprehensive service spans from gene optimization and vector construction to high-density suspension culture and multi-step chromatography for high-purity protein isolation. We guarantee the production of functional, correctly folded proteins, including viral proteins, multi-subunit enzymes, and vaccine antigens, ensuring clients receive high-quality material for structural studies, drug screening, and therapeutic development.
Get a QuoteThe key advantage of using Sf9 Cells lies in the power of the Baculovirus Expression Vector System (BEVS). BEVS utilizes the lytic cycle of the baculovirus to drive exceptionally high-level expression of foreign genes, leveraging the host's robust eukaryotic machinery (ER/Golgi). This system is highly efficient for proteins requiring proper folding, oligomerization, and disulfide linkage, resulting in biologically active products. Our platform employs optimized virus stocks, tailored high-density suspension culture protocols, and efficient purification strategies to maximize soluble, active protein yield, often resulting in higher volumetric productivity than transient mammalian systems for certain proteins.
Baculovirus Construction (BV)
Rapid cloning of the target gene into the baculovirus transfer vector, followed by homologous recombination (e.g., Bac-to-Bac® system) to generate high-titer recombinant baculovirus (rBV) stock.
Multi-Gene Expression
Co-expression of multiple subunits or chaperones using polyhedrin or p10 promoters in a single rBV or via co-infection strategies to ensure correct assembly (e.g., multi-subunit complexes).
Suspension Culture & MOI
Optimization of culture conditions (media, cell density) and Multiplicity of Infection (MOI) for Sf9 cells to maximize yield and protein quality during the lytic cycle.
Affinity Chromatography (AC)
Primary capture using highly specific tags (His-tag, FLAG) from the culture medium (for secreted proteins) or cell lysate (for intracellular proteins), achieving high initial purity.
Chromatography Polishing
Utilizing Ion Exchange (IEX) and Size Exclusion Chromatography (SEC) to remove residual host cell proteins (HCPs) and baculovirus components, ensuring final monomeric purity ($>95\%$).
Protease Deficiency Host
Utilization of engineered protease-deficient Sf9 cell lines (or addition of inhibitors) to maintain the integrity of the secreted protein throughout the culture and harvest phases.
Vaccine Antigens/VLPs
Excellent platform for the high-yield production and self-assembly of Virus-Like Particles (VLPs) and other highly immunogenic vaccine candidates.
Intracellular Complex Enzymes
High-level expression of multi-subunit or membrane-associated enzymes (e.g., kinases, GPCRs) requiring complex eukaryotic folding and PTMs.
Secreted Eukaryotic Proteins
Production of growth factors, signaling molecules, and secreted domains, leveraging the host's efficient secretion pathway.
A systematic process from gene cloning to final quality-controlled recombinant protein.
1. Gene & rBV Construction
2. Expression Optimization (MOI/Time)
3. High-Density Culture & Harvest
4. Multi-Step Purification & QC
Codon optimize gene for Sf9 cells; design purification tags and required regulatory elements.
Clone gene into the baculovirus transfer vector (BV); generate high-titer recombinant baculovirus (rBV) stock.
Perform small-scale titering of the rBV stock ($\text{pfu/mL}$).
Establish optimal infection parameters: Multiplicity of Infection (MOI) and time-post-infection (TPI).
Test expression across different host cell lines (Sf9 vs. Hi5) to select the highest-yield combination.
Perform initial analysis of product solubility and folding (Western Blot/Activity Assay).
Purification: Execute multi-step chromatography (Affinity, IEX, SEC) based on the protein's characteristics.
QC: Purity analysis (SDS-PAGE $>95\%$ guaranteed), Mass Spectrometry (MS) for identity, and specialized Glycan/Functionality assays upon request.
Delivery of purified protein, Certificate of Analysis (CoA), and documentation of all upstream/downstream protocols.
Ultra-High Expression Levels
The Baculovirus Expression Vector System (BEVS) drives exceptionally high expression, often achieving grams per liter yield of soluble protein, suitable for high-volume needs.
Complex Protein Assembly
The eukaryotic host performs correct folding, disulfide bond formation, and the assembly of large, multi-subunit protein complexes and Virus-Like Particles (VLPs).
Rapid Scalability
Sf9 cells grow readily in high-density suspension culture in serum-free media, allowing for rapid and cost-effective scale-up to large-volume bioreactors.
Glycoengineered Hosts
We utilize engineered Sf9 cell lines with modifications (KO/KI) to the glycosylation pathway to produce humanized N-glycans, improving suitability for therapeutic use.
1. What is the BEVS system and why is it so high-yield?
The BEVS (Baculovirus Expression Vector System) uses the strong viral polyhedrin or p10 promoter to drive high expression during the lytic cycle of the virus, allowing for massive production of the target protein shortly before the host cell lyses.
2. What is the optimal harvest time (TPI) for maximum yield?
The optimal harvest time (Time Post Infection, TPI) is critical and determined experimentally, usually between 48 and 96 hours post-infection, just before significant cell lysis or product degradation occurs.
3. Can you produce multi-subunit protein complexes?
Yes. The BEVS system is highly effective for multi-subunit assembly, often using multiple expression cassettes in a single baculovirus or co-infecting with different baculovirus stocks to ensure correct stoichiometry.
4. How do you address the non-human glycosylation issue in Sf9 cells?
We offer specialized services using Glycoengineered Sf9 Cell Lines where native glycosylation genes have been knocked out and human glycosylation genes have been stably knocked in (via CRISPR) to produce human-like N-glycans.
5. How is the final purified product's quality verified?
Final QC includes SDS-PAGE/SEC for purity ($>95\%$), Western Blot/Mass Spec for identity, and functional assays (e.g., enzyme activity, binding affinity). Specialized PTM analysis is also available.
6. Do you recommend Sf9 or High Five (Hi5) cells?
The choice depends on the protein. Sf9 is the general workhorse and is easier to grow. Hi5 cells (T. ni) generally produce higher yields, especially for secreted proteins, due to higher post-infection metabolic activity.
7. Is the final product secreted or intracellular?
Both. If a signal peptide is included, the protein is secreted into the medium, simplifying purification. Intracellular expression is used for proteins that need complex assembly in the cytoplasm or are toxic to the host's secretion pathway.
8. What initial input is required to start an expression project?
We require the specific protein sequence (amino acid or DNA), the desired purification tag, and the target quantity and purity level for the final recombinant protein.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.